Paget's disease of the bone: observations after cessation of long-term synthetic salmon calcitonin treatment.
Thirteen patients with Paget's disease of the bone were treated with subcutaneous injections of synthetic salmon calcitonin (SCT) for a mean period of 22 months at doses of 50-100 MCR units daily or 3 times a week. They manifested symptomatic improvement and significant reductions in serum alkaline phosphatase and urinary hydroxyproline excretion during SCT administration. Following discontinuation of SCT, symptomatic improvement was maintained in 10 patients for up to one year, whereas a recurrence of symptoms was seen in only 3 patients. The serum alkaline phosphatase generally showed a return toward pretreatment values 6 months after discontinuation of SCT, whereas urinary hydroxyproline remained depressed for up to a year.
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D002116:Calcitonin / Q000276:immunology / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000652:urine; D012008:Recurrence; D013997:Time Factors
D002116:Calcitonin; D000469:Alkaline Phosphatase; D006909:Hydroxyproline